most likely represent a cluster of cases in the SWSLHD area but may alternatively reflect either better recognition or increased incidence of CJD.

034 PROSPECTIVE STUDY OF 24-HOUR LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY FOR UNRESPONSIVE FREEZING OF GAIT

Sai Nagaratnam*, Florence Ching-Fen Chang, David S Tsui, Neil Mahant, Nigel Wolfe, Samuel D Kim, Ainhoa D Ha, Jane M Griffith, Victor SC Fung. *Department of Neurology, Westmead Hospital, Sydney, NSW, Australia*

10.1136/jnnp-2019-anzan.31

Introduction We report a prospective, open-label study of 24-hour levodopa-carbidopa intestinal gel (LCIG) as treatment for levodopa 'unresponsive' freezing of gait (FOG) associated with Parkinson's disease.

Method 14 patients with disabling FOG, documented as being levodopa 'unresponsive' following dose cycle assessment, were commenced on continuous 24-hour infusion LCIG therapy with the night-time rate at 50–80% of the daytime infusion rate. Patients underwent baseline and 6 months gait assessments, documentation of their falls frequency and completed FOG questionnaires. The statistical analysis was performed with SPSS 25 software (IBM), using Wilcoxon Signed Rank test and $p < 0.05$ was set as statistically significant.

Result The fall frequency score reduced from 3 to 1 at 6 months ($p=0.011$). The FOG questionnaire was 19.3 ± 1.5 at baseline and reduced to 16.0 ± 1.7 , at 6 months, respectively ($p=0.039$). The mean 360 degree turn time was not significantly changed ($p=0.77$). The daytime LCIG infusion rate was not significantly different before and after 24-hour LCIG therapy ($p=0.315$). 7 subjects developed visual hallucinations, one required temporary withdrawal from 24-hour LCIG, but as FOG worsened on 16-hour LCIG, he elected to recommence 24-hour LCIG infusion with improvement in FOG with a reduction in falls. 1 subject had postural hypotension which was ameliorated after adjustment of LCIG infusion rate.

Conclusion We provide further evidence that 24-hour LCIG therapy can reduce levodopa 'unresponsive' FOG and associated falls.

035 VALPROATE-INDUCED PARKINSONISM 'AN EARLY WARNING': CASE REPORTS AND REVIEW OF LITERATURE

¹Shoaib Dal*, ^{1,2}Scott Whyte. ¹Central Coast Local Health District, Gosford, NSW, Australia; ²University of Newcastle, Newcastle, NSW, Australia

10.1136/jnnp-2019-anzan.32

Introduction We describe two cases of valproate-induced parkinsonism, where the parkinsonian features develop after commencing valproate (VPA), in a time frame and manner well described by previous publications.¹ In contrast to the published literature, that has short duration of follow-up, we have had a prolonged follow-up of these two cases, who initially improved on ceasing valproate, but then after a period progressed again, with the development of levodopa-responsive asymmetrical Parkinson's disease.²

Cases 67 years old man, on VPA 500 mg twice a day for seizures since 2008, developed new rest, re-emergent left hand tremor and hypomimia in 2012. Within months, the parkinsonism progressed to decremental bradykinesia, cog-wheel rigidity and hypophonia. The symptoms initially improved with changing VPA to levetiracetam; however, the disease reappeared after 6 months and although levodopa-responsive, it has been progressive since then.

88 years old man, on VPA 700 mg twice a day for seizures since 2010, developed upper limb decremental bradykinesia, cog-wheel rigidity, camptocormia and rest, re-emergent tremor in hands in 2011. The parkinsonism improved significantly with cessation of VPA; however, the disease re-emerged after 2 years and has been progressive since then.

Conclusion VPA may be responsible for unmasking underlying subclinical parkinsonism and these patients represent an earlier onset of Parkinson's disease related to VPA exposure, rather than a purely drug related parkinsonian dysfunction. These cases also highlight the importance of long-term follow up in VPA-induced parkinsonism. These observations are an important consideration for clinicians treating patients with parkinsonian features secondary to VPA exposure.

REFERENCES

1. Brugger F, Bhatia KP, Besag FM. Valproate-associated parkinsonism: a critical review of the literature. *CNS Drugs* 2016;**30**(6):527–540.
2. Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. *Am J Geriatr Pharmacother* 2011;**9**(6):405–412.

036 THE IMPACT OF A CLINICAL SUPPORT TOOL ON STROKE KEY PERFORMANCE INDICATORS

Khaled Alanati*, James Evans. *Department of Neuroscience, Gosford Hospital, Gosford, NSW, Australia*

10.1136/jnnp-2019-anzan.33

Introduction Adherence to key performance indicators (KPIs) in stroke care is associated with better outcomes.^{1–6} The complexity in management of acute strokes, however, has created barriers towards delivering best care with plateauing of KPIs as measured by The National Stroke Foundation Clinical Audit.

We examined the impact on stroke KPIs in our local health district of a web-based decision support stroke platform which provides clinicians with up-to-date information about the patient's management flagging potential areas for improvement, allowing treatment to be optimised in real time.

Methods Six months following the introduction of the platform we performed a retrospective analysis of Electronic medical records of patients admitted to Gosford hospital with acute stroke between June 2018 and September 2018 assessing access to the stroke unit as well as being discharged on appropriate secondary prophylactics, including antihypertensives and correct antithrombotic therapy. Patients whose direction of care was palliative and patients with documented contraindication to secondary prophylactics were excluded.

Results Over four months, 136 patients presented with acute ischaemic stroke and 11 patients had a haemorrhagic stroke. 49 ischaemic stroke patients had atrial fibrillation. Stroke unit access was higher following its introduction in 2018 compared